Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

The reactivity-driven biochemical mechanism of covalent KRASG12C inhibitors.

Hansen R, Peters U, Babbar A, Chen Y, Feng J, Janes MR, Li LS, Ren P, Liu Y, Zarrinkar PP.

Nat Struct Mol Biol. 2018 May 14. doi: 10.1038/s41594-018-0061-5. [Epub ahead of print]

PMID:
29760531
2.

Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor.

Janes MR, Zhang J, Li LS, Hansen R, Peters U, Guo X, Chen Y, Babbar A, Firdaus SJ, Darjania L, Feng J, Chen JH, Li S, Li S, Long YO, Thach C, Liu Y, Zarieh A, Ely T, Kucharski JM, Kessler LV, Wu T, Yu K, Wang Y, Yao Y, Deng X, Zarrinkar PP, Brehmer D, Dhanak D, Lorenzi MV, Hu-Lowe D, Patricelli MP, Ren P, Liu Y.

Cell. 2018 Jan 25;172(3):578-589.e17. doi: 10.1016/j.cell.2018.01.006.

PMID:
29373830
3.

Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells.

Kharas MG, Janes MR, Scarfone VM, Lilly MB, Knight ZA, Shokat KM, Fruman DA.

J Clin Invest. 2017 Jun 1;127(6):2438. doi: 10.1172/JCI95182. Epub 2017 Jun 1. No abstract available.

4.

Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State.

Patricelli MP, Janes MR, Li LS, Hansen R, Peters U, Kessler LV, Chen Y, Kucharski JM, Feng J, Ely T, Chen JH, Firdaus SJ, Babbar A, Ren P, Liu Y.

Cancer Discov. 2016 Mar;6(3):316-29. doi: 10.1158/2159-8290.CD-15-1105. Epub 2016 Jan 6.

5.

Resistance to mTOR kinase inhibitors in lymphoma cells lacking 4EBP1.

Mallya S, Fitch BA, Lee JS, So L, Janes MR, Fruman DA.

PLoS One. 2014 Feb 21;9(2):e88865. doi: 10.1371/journal.pone.0088865. eCollection 2014.

6.

Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function.

Lim S, Saw TY, Zhang M, Janes MR, Nacro K, Hill J, Lim AQ, Chang CT, Fruman DA, Rizzieri DA, Tan SY, Fan H, Chuah CT, Ong ST.

Proc Natl Acad Sci U S A. 2013 Jun 18;110(25):E2298-307. doi: 10.1073/pnas.1301838110. Epub 2013 Jun 4.

7.

Selective inhibition of phosphoinositide 3-kinase p110α preserves lymphocyte function.

So L, Yea SS, Oak JS, Lu M, Manmadhan A, Ke QH, Janes MR, Kessler LV, Kucharski JM, Li LS, Martin MB, Ren P, Jessen KA, Liu Y, Rommel C, Fruman DA.

J Biol Chem. 2013 Feb 22;288(8):5718-31. doi: 10.1074/jbc.M112.379446. Epub 2012 Dec 28.

8.

Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia.

Janes MR, Vu C, Mallya S, Shieh MP, Limon JJ, Li LS, Jessen KA, Martin MB, Ren P, Lilly MB, Sender LS, Liu Y, Rommel C, Fruman DA.

Leukemia. 2013 Mar;27(3):586-94. doi: 10.1038/leu.2012.276. Epub 2012 Oct 1.

9.

The translational landscape of mTOR signalling steers cancer initiation and metastasis.

Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A, Shi EY, Stumpf CR, Christensen C, Bonham MJ, Wang S, Ren P, Martin M, Jessen K, Feldman ME, Weissman JS, Shokat KM, Rommel C, Ruggero D.

Nature. 2012 Feb 22;485(7396):55-61. doi: 10.1038/nature10912.

10.

The in vivo evaluation of active-site TOR inhibitors in models of BCR-ABL+ leukemia.

Janes MR, Fruman DA.

Methods Mol Biol. 2012;821:251-65. doi: 10.1007/978-1-61779-430-8_15.

PMID:
22125070
11.

Sphingolipid-based drugs selectively kill cancer cells by down-regulating nutrient transporter proteins.

Romero Rosales K, Singh G, Wu K, Chen J, Janes MR, Lilly MB, Peralta ER, Siskind LJ, Bennett MJ, Fruman DA, Edinger AL.

Biochem J. 2011 Oct 15;439(2):299-311. doi: 10.1042/BJ20110853.

12.

Next-generation flow cytometry.

Janes MR, Rommel C.

Nat Biotechnol. 2011 Jul 11;29(7):602-4. doi: 10.1038/nbt.1919. No abstract available.

PMID:
21747386
13.

B-1 cell lymphoma in mice lacking the steroid and xenobiotic receptor, SXR.

Casey SC, Nelson EL, Turco GM, Janes MR, Fruman DA, Blumberg B.

Mol Endocrinol. 2011 Jun;25(6):933-43. doi: 10.1210/me.2010-0486. Epub 2011 Mar 24.

14.

Targeting TOR dependence in cancer.

Janes MR, Fruman DA.

Oncotarget. 2010 May;1(1):69-76.

15.

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor.

Janes MR, Limon JJ, So L, Chen J, Lim RJ, Chavez MA, Vu C, Lilly MB, Mallya S, Ong ST, Konopleva M, Martin MB, Ren P, Liu Y, Rommel C, Fruman DA.

Nat Med. 2010 Feb;16(2):205-13. doi: 10.1038/nm.2091. Epub 2010 Jan 13.

16.

Immune regulation by rapamycin: moving beyond T cells.

Janes MR, Fruman DA.

Sci Signal. 2009 Apr 21;2(67):pe25. doi: 10.1126/scisignal.267pe25.

PMID:
19383976
17.

Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells.

Kharas MG, Janes MR, Scarfone VM, Lilly MB, Knight ZA, Shokat KM, Fruman DA.

J Clin Invest. 2008 Sep;118(9):3038-50. doi: 10.1172/JCI33337. Erratum in: J Clin Invest. 2017 Jun 1;127(6):2438.

Supplemental Content

Loading ...
Support Center